Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
336 Results for "
b′ domain
" in MedChemExpress (MCE) Product Catalog:
Products (336)
336 Results for "b′ domain" in MCE Product Catalog:
13
13 Publications Verification
Target:
Research Areas:
PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo .
12
12 Cited Publications
Target:
Research Areas:
EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
10
10 Cited Publications
Cat. No.: HY-P7863
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: C3; Complement Component 3; Complement C3; C3a Anaphylatoxin; CPAMD1; Prepro-C3; ARMD9; Epididymis Secretory Sperm Binding Protein Li 62p; C3a; Acylation-Stimulating Protein Cleavage Product; C3b; HEL-S-62p; C3 And PZP-Like Alpha-2-Macroglobulin domain-Co
Species:
Mouse
Source:
E. coli
8
Target:
Research Areas:
8
Target:
Research Areas:
7
7 Cited Publications
Cat. No.: HY-P7695
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: C5; C3 And PZP-Like Alpha-2-Macroglobulin domain-Containing Protein 4; Complement C5; C5a Anaphylatoxin; CPAMD4; Prepro-C5; Complement Component 5; Anaphylatoxin C5a Analog; C5a; ECLZB; C5b; C5D
Species:
Mouse
Source:
E. coli
7
7 Cited Publications
Cat. No.: HY-P7862
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: C3; Complement Component 3; Complement C3; C3a Anaphylatoxin; CPAMD1; Prepro-C3; ARMD9; Epididymis Secretory Sperm Binding Protein Li 62p; C3a; Acylation-Stimulating Protein Cleavage Product; C3b; HEL-S-62p; C3 And PZP-Like Alpha-2-Macroglobulin domain-Co
Species:
Human
Source:
E. coli
6
Target:
Research Areas:
NSC 663284 (DA-3003-1) is a potent, cell-permeable, and irreversible Cdc25 dual specificity phosphatase inhibitor, has an IC50 for Cdc25B2 of 0.21 μM. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B(2), and Cdc25C with Ki values of 29, 95, and 89 nM, respectively . NSC 663284 inhibits NSD2 (IC50 of 170 nM) through a direct interaction with the catalytic SET domain (Kd of 370 nM) .
4
Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC50s of 2, 25 and 0.9 nM for FLT3, TrkA and JAK2, respectively. Lestaurtinib induces apoptosis and cycle arrest, also can inhibit growth of tumor .
3
Target:
Research Areas:
PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. PBIT inhibits JARID1B (KDM5B or PLU1) histone demethylase with an IC50 of about 3 μM . PBIT also inhibits JARID1A and JARID1C with IC50s of 6 μM and 4.9 μM, respectively .
3
3 Cited Publications
Cat. No.: HY-P99126
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-P74394
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VTCN1; V-Set domain Containing T Cell Activation Inhibitor 1; B7-H4; B7H4; B7h.5; B7S1; B7x; V-Set domain-Containing T-Cell Activation Inhibitor 1; Immune Costimulatory Protein B7-H4; B7 Superfamily Member 1; B7 Family Member, H4; B7 Homolog 4; FLJ22418; T Cell Costimulatory Molecule B7x; T-Cell Costimulatory Molecule B7x; Protein B7S1; PRO1291; VCTN1
Species:
Mouse
Source:
HEK293
2
2 Cited Publications
Cat. No.: HY-P71575
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TEAD4; RTEF1; Prev. TCF13L1; TEA domain Family Member 4 Isoform 1 Variant; Transcriptional Enhancer Factor TEF-3; Transcriptional Enhancer Factor 1-Related; TEA domain Family Member 4; TEA domain Family Member 4, Isoform CRA_b; TEFR-1; Related Transcripti
Species:
Mouse
Source:
E. coli
1
1
1
1 Cited Publications
Cat. No.: HY-P10579
CAS No.: 2225868-19-7
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P75335
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CLEC1B; C-Type Lectin domain Family 1, Member B; C-Type Lectin domain Family 1 Member B; 1810061I13Rik; CLEC2; PRO1384; CLEC-2; QDED721; C-Type Lectin-Like Receptor 2
Species:
Mouse
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P72815
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ADAM17; Snake Venom-Like Protease; Prev. TACE; ADAM Metallopeptidase domain 18; CSVP; Uncharacterized Protein ADAM17; Disintegrin And Metalloproteinase domain-Containing Protein 17; TNF-Alpha Converting Enzyme; TNF-Alpha Convertase; CD156b Antigen; CD156B
Species:
Rat
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P78717
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: ADAM17; Snake Venom-Like Protease; Prev. TACE; ADAM Metallopeptidase domain 18; CSVP; Uncharacterized Protein ADAM17; Disintegrin And Metalloproteinase domain-Containing Protein 17; TNF-Alpha Converting Enzyme; TNF-Alpha Convertase; CD156b Antigen; CD156B
Species:
Mouse
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P74395
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: VTCN1; V-Set domain Containing T Cell Activation Inhibitor 1; B7-H4; B7H4; B7h.5; B7S1; B7x; V-Set domain-Containing T-Cell Activation Inhibitor 1; Immune Costimulatory Protein B7-H4; B7 Superfamily Member 1; B7 Family Member, H4; B7 Homolog 4; FLJ22418;
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
